Table 1.

Quality-adjusted life year values attached to health states within the model, including references and upper and lower limits explored in the sensitivity analysis

Health state	QALY valuesa	Definition information/source reference	Sensitivity analysis
			Low	High
Biopsy	−0.05	Liu et al. [34], Canadian Agency for Drugs and Technologies in Health [56]	0.00	−0.10
Chronic HCV, no fibrosis	0.92	ADVANCE and REALIZE, Poordad et al. [35], Bacon et al. [36]	0.89	0.98
Metavir 1	0.92	ADVANCE and REALIZE, Bacon et al. [36], Poordad et al. [35]	0.89	0.96
Metavir 2	0.89	ADVANCE and REALIZE, Bacon et al. [36], Poordad et al. [35]	0.86	0.93
Metavir 3	0.89	Bacon et al. [36], Poordad et al. [35]	0.86	0.93
Compensated cirrhosis	0.85	Wells et al. [37]	0.80	0.90
Decompensated cirrhosis	0.74	Wells et al. [37]	0.70	0.78
HCC with compensated  cirrhosis	0.28	Wells et al. [37]	0.25	0.35
HCC with decompensated  cirrhosis	0.3	Wells et al. [37]	0.25	0.35
HCC without cirrhosis	0.44	Grishchenko et al. [9]	0.43	0.45
Palliative care	0.28	Assumption: Wells et al. [37], Grishchenko et al. [9] compared with the health  technology assessment of Sorafanib—Connock et al. [65]—SHARP trial  showed no quality of life change with Sorafanib	0.25	0.35
Following successful  ablation or resection	0.7	Argeudas et al. [2]	0.62	0.84
Recurrent HCC	0.3	Assumption from considering Wells et al. [37] and Grishchenko et al. [9]	0.25	0.35
Transplant recipient	0.73	Thompson Coon et al. [39]	0.67	0.78

HCV Hepatitis virus C, HCC hepatocellular carcinoma, Metavir system (numbers refer to stages) to quantify the degree of inflammation and fibrosis of a liver biopsy

^aQALY value is the quality-adjusted life year value (utility value for undergoing procedures or linked to a given health state)